论文部分内容阅读
肿瘤浸润性淋巴细胞（TIL）和脐血淋巴因子激活杀伤（LAK）细胞在含重组白细胞介素2（rlL－2）的完全培养基中可大量扩增培养，体外培养肿瘤组织的TIL及癌性腹水的淋巴细胞对自体瘤细胞（黑色素瘤，卵巢囊腺癌，大网膜转移性腺癌及癌性腹水）有明显的杀伤作用，胎儿脐血中分离培养的LAK细胞对肿瘤细胞也有较强的杀伤作用，在效靶比例分别为20：1和40：1时，对肿瘤细胞的杀伤作用后者均明显高于前者（P=0.025和P=0．01），且TIL对自体瘤细胞的杀伤作用明显高于脐血LAK细胞（P＜0．01），为临床应用TIL和脐血细胞提供实验依据。
Tumor infiltrating lymphocytes (TIL) and umbilical cord blood lymphokine activated killer (LAK) cells can be extensively expanded in complete medium containing recombinant interleukin 2 (rlL-2), and TIL and tumors of tumor tissues can be cultured in vitro. Ascites lymphocytes have a significant killing effect on autologous tumor cells (melanoma, ovarian cystadenocarcinoma, omental metastatic adenocarcinoma, and cancerous ascites). LAK cells isolated from fetal umbilical cord blood are also strong against tumor cells. In the killing effect, the killing effect on tumor cells was significantly higher than that of the former when the effect target ratio was 20:1 and 40:1, respectively (P=0.025 and P=0.01), and TIL on autologous tumor cells. The killing effect was significantly higher than cord blood LAK cells (P<0.01), providing experimental basis for the clinical application of TIL and umbilical cord blood cells.